Leerink Partners Maintains Incyte(INCY.US) With Buy Rating, Cuts Target Price to $92

Moomoo News01:32 ET

Analysts Offer Insights on Healthcare Companies: InflaRx (IFRX), Eli Lilly & Co (LLY) and Incyte (INCY)

TipRanks20:46 ET

Incyte Is Maintained at Equal-Weight by Morgan Stanley

Dow JonesMar 24 07:57 ET

Incyte Analyst Ratings

BenzingaMar 24 07:48 ET

Morgan Stanley Maintains Incyte(INCY.US) With Hold Rating, Cuts Target Price to $65

Moomoo NewsMar 24 06:31 ET

Incyte's Hold Rating: Balancing Pipeline Challenges and Established Product Valuation

TipRanksMar 24 06:02 ET

William Blair Maintains Incyte(INCY.US) With Hold Rating

Moomoo NewsMar 22 19:32 ET

Incyte (INCY) Was Downgraded to a Hold Rating at William Blair

TipRanksMar 22 10:59 ET

Monday.com, Incyte, Lucid, Bloom, EQT: Trending by Analysts

TipRanksMar 22 05:05 ET

Incyte Is Maintained at Hold by Truist Securities

Dow JonesMar 18 10:20 ET

Incyte Price Target Maintained With a $92.00/Share by Guggenheim

Dow JonesMar 18 10:14 ET

A Quick Look at Today's Ratings for Incyte(INCY.US), With a Forecast Between $68 to $100

Moomoo NewsMar 18 09:00 ET

Incyte Cut to Market Perform From Outperform by William Blair

Dow JonesMar 18 07:45 ET

Incyte Analyst Ratings

BenzingaMar 18 07:35 ET

Incyte's Stock Downgraded to Sell Amid Disappointing Drug Data and Market Challenges

TipRanksMar 18 07:31 ET

Incyte (INCY) Receives a Hold From Wells Fargo

TipRanksMar 18 06:23 ET

Incyte's Promising Phase 3 Results and Market Potential Drive Buy Rating

TipRanksMar 18 06:07 ET

TD Cowen Reaffirms Their Buy Rating on Incyte (INCY)

TipRanksMar 17 17:52 ET

Wells Fargo Cuts Price Target on Incyte to $58 From $70

MT NewswiresMar 17 10:33 ET

Buy Rating for Incyte's Povorcitinib Despite Mixed Trial Results, Highlighting Potential in Biologic-Experienced Subgroups

TipRanksMar 17 08:01 ET